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     INTRODUCTION 
  Dengue fever is a rapidly increasing public health problem 
in tropical and subtropical regions with a large percentage of 
the world’s population at risk.  1   Resource-poor countries are 
particularly hard hit because of inadequate public health infra-
structure, lack of resources to combat the vector, and limited 
health care services to manage cases.  2   The most recent esti-
mates suggested 50 million infections and 20,000 deaths occur 
each year.  1   Several tetravalent dengue vaccine candidates are 
in phase 1 and 2 clinical trials and one candidate has entered a 
large-scale efficacy and safety trial.  3,  4   Depending on the results 
of these and future clinical trials, a dengue vaccine could be 
licensed in the next 5 years. 
  The Pediatric Dengue Vaccine Initiative (PDVI) is a prod-
uct development partnership  5   whose goal it is to accelerate 
development, evaluation, and introduction of dengue vaccines 
in endemic countries.  6   To understand the economic impact of 
the disease and to strategically plan for further research, PDVI 
conducted a systematic review of the literature and convened 
a panel of experts to assess the results and provide recom-
mendations on the priorities and methodology for conducting 
further research, especially disease burden and cost-of-illness 
studies, comparative analyses, and modeling for planning vac-
cine introduction strategies. 
   MATERIALS AND  METHODS 
  Expert  panel.     In April 2008, the PDVI sponsored a meeting 
of experts (coauthors) in health economics or dengue in 
Antwerp, Belgium, to review the existing literature on 
dengue health economics, identify future research needs, and 
provide recommendations on priorities and methodology for 
conducting further research. Future research was prioritized 
by the panel on the basis of their expert opinion and past 
experience after considering estimated study costs, surmised 
interest to decision makers on dengue vaccine development 
and introduction, and the assumption that an approved dengue 
vaccine would be available within 5 years. Need-based priority 
was rated numerically, 1 = urgent, 2 = needed, 3 = optional. The 
panel then assigned a time period during which the needed 
studies should be started so the results are available for 
planning when a dengue vaccine becomes available; 1–2 years, 
2–4 years, and 5–6 years. Because the interest in economic 
studies varies based on the needs of different stakeholders 
in dengue vaccine, interest in each type of study result was 
rated from high to low on the basis of the expert opinion of 
the panel. 
   Literature  search.     After designing an agreed search strategy, 
inclusion/exclusion criteria, and quality rating, in March 
2008 (updated in January 2010), MEB conducted searches 
of published literature for economic studies of dengue in 
the following data bases, without restriction to publication 
year or language: U.S. National Library of Medicine and 
the National Institutes of Health Medical (PubMed) (1966–
2009); Excerpta Medica Database (EMBASE) (1983–2009); 
Latin American and Caribbean Health Sciences Database 
(LILAC) (1967–2009); American Economic Association’s 
electronic bibliography of economic literature (EconLit) 
(1969–2009); and World Health Organization (WHO) library 
(WHOLIS) (1985–2009). The search criteria combined the 
medical subject headings (MeSH) “dengue,” “economics,” 
“health economics,” “costs and cost analysis,” “cost of illness,” 
“quality of life,” with the text words “economic,” “cost,” “best 
practice analysis,” “budget impact,” “DALY,” and “QALY.” 
Unpublished reports were also included if they were identified 
in a database (i.e., LILAC, WHOLIS, EconLit) or referenced 
in a publication identified in the initial search. Abstracts and 
full text of identified manuscripts were reviewed and the 
following inclusion criteria were applied: 1) analyzed both 
costs and clinical outcomes, 2) provided detailed methods, 
and 3) involved original data analysis. Excluded were reviews, 
editorials, and studies involving previously published data. The 
quality of data was assessed (by MEB) according to the scale 
developed by Sackett and others  7   and recommended by the 
York Centre  8  but modified for dengue ( Table 1 ). After piloting, 
the data abstraction instrument was applied to all included 
studies (MEB). The variables abstracted became the column 
headings for   Tables 2   and   3  . The full text of included studies 
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 Table 1 
    Quality grading scale for economic studies of dengue  7,  8   
Quality score Description
I Evaluation of important alternative interventions 
comparing all clinically relevant outcomes 
(e.g., non-hospitalized, hospitalized, or dengue 
hemorrhagic fever [DHF], and death) against 
appropriate cost measurement, and including 
a clinically sensible sensitivity analysis
II Evaluation of important alternative interventions 
comparing a limited number of outcomes against 
appropriate cost measurement, but including 
a clinically sensible sensitivity analysis
III Evaluation of important alternative interventions 
comparing all clinically relevant outcomes against 
inappropriate cost measurement, but including 
a clinically sensible sensitivity analysis
IV Evaluation without a clinically sensible sensitivity 
analysis
V Expert opinion with no explicit critical appraisal, 
based on economic theory
was circulated to all coauthors before convening the expert 
panel and after the update search was completed. Results 
and discussion of the studies were synthesized by MEB and 
circulated for additional comments to all coauthors. 
                 Classification scheme.   We categorized identified publications 
according to economic methods (macroeconomic versus 
microeconomic) and study objectives (e.g., quantify disease 
burden or assess the impact interventions [comparative 
analysis]). 
  Disease burden studies were categorized by the metric used 
to quantify burden—non-monetized units (e.g., DALY  9 )  or 
monetized units (e.g., dollars); the latter being classified as a 
cost-of-illness (COI) study. The COI studies were categorized 
by level or perspective of the payer (e.g., government, health-
care system, household) and government perspective was fur-
ther subdivided into public health costs and budget impact of 
vaccine introduction. 
  Comparative analyses were categorized by type of interven-
tion (i.e., vaccine versus vector control) and the value used 
to make the comparisons: 1) cost-effectiveness analyses used 
unvalued or natural health gains (e.g., cases of dengue, deaths 
averted, life-years gained); 2) cost-utility analyses valued out-
comes in units that reflected measures of morbidity and mor-
tality, such as quality (QALYs) or disability-adjusted life years 
(DALYs); and 3) cost-benefit analyses converted health out-
comes into monetary units to enable comparisons between 
interventions in the health and other sectors (e.g., education) 
to estimate return on investment. 
    RESULTS 
  Our search indentified 748 citations (  Figure 1  ). Of 
these, 43 were dengue-related economic studies that ful-
filled   the inclusion criteria.  10–  55      Forty-one  used  micro-
economic   methods: 32 report economic burden of dengue 
( Table  2 ), 10–12,15–18,20–32,34–37,41,42,46,47,49–55  and nine are compar-
ative economic analyses assessing various interventions 
( Table  3 ). 13,14,33,38,39,43–45,48  The remaining two were a willingness-
to-pay (WTP) study and a policymaker survey.  19,  40  
   Disease  burden.     Without  monetization.    Eight  studies 
expressed the dengue burden in DALYs  10,17,22,29,31,32,34,53–55  
This measure has been used since the early 1990s to 
determine disease burden and facilitate disease comparison 
and prioritization.  9,29,53,54  The DALY is a summary measure 
essentially combining the occurrence and duration of a disease, 
with its lethality and severity (expressed in a “disability score,” 
a higher score signifying worse health). However, there has 
been great variability in reported dengue disease burden using 
DALYs, which has occurred for several reasons. Early on only 
the more severe form of dengue, dengue hemorrhagic fever 
(DHF), was measured or reported but not the less severe 
dengue fever (DF).  56   As a result, only DHF incidence was used 
in early DALY calculations.  53   Subsequently, cohort studies in 
Asia showed that DHF represented a small proportion of 
symptomatic infections,  57–  59   and its sole use to define a case 
would underestimate dengue cases by a factor of 2- to 10-fold. 
  A second factor related to variability in reported dengue 
disease burden has been inconsistent application of disability 
scores, which are a measure of disease severity and essential 
to the DALY calculation. Early scores were probably too low, 
ranging from 0.172 to 0.211 (at that time equivalent to uncom-
plicated malaria or a radius fracture in a hard cast), whereas 
the duration of illness of 30 days  29,53,54  was too long.  10,57–59  An 
early study that used only nationally reported DHF cases used 
a disability score of 0.22 but shortened the duration of illness 
to 20 days,  17   which reduced the DALY estimate by 30%. 
  In 2004, WHO revised the burden estimates for dengue.  55  
For DHF, the disability score was increased to 0.5 but the dura-
tion of illness was shortened to 11 days, which resulted in the 
same DALYs obtained in 1990 when the disability score was 
~0.2 and duration of illness was 30 days. More importantly, DF 
was included in the new estimates, with an assigned disability 
score of 0.211 and illness duration of 5.5 days. In comparison, 
an uncomplicated febrile episode of malaria, which is often in 
the differential diagnosis of DF because of the similarity in 
clinical presentation and severity, was increased from its 1990 
disability score of 0.21 to a score of 0.471, more than doubling 
the DALY estimate.  60  
  Because patients with DHF require hospitalization and can-
not care for themselves, Meltzer and others used a 0.81 disabil-
ity score  34  (equivalent to a severe migraine  53   or diseases that 
interfere with one’s ability to care for oneself) but used shorter 
durations of each type of illness  34   to be consistent with clini-
cal data,  47,  61   which more than doubled the estimated DALYs 
( Table 2 ). Subsequent studies have also used this higher disabil-
ity score for DHF.  10,22,32  Meltzer and others also documented 
that non-hospitalized cases, which typically are limited to DF, 
account for the greater portion of dengue disease burden,  34  
a finding confirmed by subsequent studies.  10,12,20,32  However, 
even in countries or regions where non-hospitalized DF is 
reported, under-reporting is still significant.  62  
 Luz and others reported that from 1986 through 2006, deaths 
accounted for the majority of the remaining disease burden 
caused by dengue after DF in Brazil, and that this proportion 
was increasing.  32  Luz and others also reported that dengue dis-
ease burden was greatest at the city level followed by state 
and national levels.  32  Although dengue is primarily a disease 
of urban centers,  2   its disease burden in rural areas has been 
increasing.  63–  65  
  The duration of disability during dengue was not fully 
examined in the identified studies. A prospective study by 
Anderson and others determined the duration of measurable 
fever in hospitalized and non-hospitalized patients rather than 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































d482 BEATTY AND OTHERS
was 6.35 and 5.32 days, respectively, for the two groups. Lum 
and others examined how dengue affected quality of life as 
measured by impact on daily activities or health domains (e.g., 
self care, mobility, cognition) using the WHO World Health 
Survey  66   and visual analog scale (VAS) from the EuroQol 
EQ-5D.  67   They found quality of life was impaired for 9 days 
among non-hospitalized patients and 13 days for hospitalized 
patients. At its lowest value, the VAS score was reduced to 
about 40% of that of its highest value, with slightly lower val-
ues for hospitalized versus ambulatory patients, and for adults 
versus children. Of eight health domains evaluated, an average 
of 5.0 were affected among non-hospitalized patients, and 6.2 
among hospitalized patients.  31   An advantage of this approach 
versus DALYs is that the patients were surveyed regarding 
how they experienced their disease, rather than that experts 
rated the severity of the disease stage. It was not clear, how-
ever, who served as respondent for children (i.e., a parent, a 
health care provider, or the study investigator).  68   Moreover, 
although this was the first study to conduct a daily assessment 
of dengue on the quality of life, DALYS were not calculated—
limiting comparability with previous studies. 
  Although the goal of using DALYs is to compare and pri-
oritize diseases based on a common metric, in the case of den-
gue significant revision in the scoring has occurred since the 
original effort was undertaken, because disease burden stud-
ies aided by improved diagnostics raised awareness of the true 
breadth and spectrum of symptomatic dengue. Still, even the 
most recent estimates by WHO, underestimate dengue disease 
burden by using disability scores half those that are used by 
author researchers in the published literature. New disease 
burden estimates from WHO are expected soon and may be 
more consistent with contemporary estimates. 
   With  monetization.       Government  perspective.     Thirteen 
studies reported the cost of illness of dengue from the govern-
ment perspective (  Table 2  )  12,16,20,23,30,35–37,41,42,46,49,51 ; eight also 
included costs from both the healthcare system and household 
perspective. The majority was conducted in Latin America 
and over 10 years ago.  20,23,36,41,42,46,49,51  Okanurak and others 
 Figure 1.        Results of systematic literature search and evaluation of identified studies.       483 HEALTH ECONOMICS OF DENGUE
showed a significant difference in dengue cost of illness 
between children (0–15 years of age) and adults (> 15 years 
of age),  37  which is consistent with clinical studies that showed 
children are less likely than adults to be symptomatic but more 
likely to have severe disease.  69,  70   Okanurak and others also 
documented a significant difference in cost of illness between 
a large referral center and provincial or community hospitals, 
although only three facilities were included in the study.  37  
Adam and others suggested that multiple facilities of the same 
type should be studied to define the degree and magnitude of 
cost variability.  71  
  All studies itemized cost, but there was variation in what 
costs were included. Anderson and others found that transpor-
tation to healthcare facilities was a significant contributor to 
outpatient costs, but this was not included in all studies.  20,23,37,49,51  
Most studies included days of lost wages,  23,  49  and some included 
the value of days children were absent from school.  12,23,46,49  The 
most inclusive COI studies were reported by Armien and oth-
ers and Suaya and others. The Armien and others study  12   was 
part of a larger eight country study coordinated by Suaya and 
others.  46   Although the same COI is reported for Panama in 
both studies, Armien and others also estimated the cost of sur-
veillance, laboratory testing, and vector control.  12,  46   Both stud-
ies also included lodging, food, and the cost of transportation 
to medical facilities for both patients and any accompanying 
or visiting family member, lost wages and productivity, which 
was assigned to used and unemployed persons and all fam-
ily members caring for the patient.  12,  46   Additionally, the use of 
multiplication factors to account for under-reporting of cases 
to national surveillance systems had a major impact on aggre-
gated cost estimates, whereas the inclusion of private health-
care providers was associated with substantially higher costs 
per case.  12,26,46,50  
  In dengue endemic countries, transmission occurs year 
round with a seasonal peak incidence (dengue season). In 
addition, cyclical epidemics occur at 3–9 year intervals, but 
high rates of transmission usually continue during the inter-
epidemic periods.  72  All studies except that by Canyon,  16  report 
data from epidemic years, and none provided data from 
non-epidemic years in the same country. Dengue epidemics 
could result in great variation in government and healthcare 
expenditures, including actual costs per case. For example, 
during a typical non-epidemic year in Brazil, 200,000 den-
gue cases were reported but during the 2002 epidemic this 
number rose to 800,000.  73   In addition, Siqueira and others  73  
showed the proportion of dengue cases that required hospi-
talization increased during epidemics.  73  While this could be 
caused by increased disease severity from biologic factors 
(virus or host),  72   it may be behavioral. Several household 
studies showed increased parental fear and concern when 
a child developed a fever during a dengue epidemic.  28,  47   In 
addition, the expert panel suggested that rationing of scarce 
resources during an epidemic may actually reduce the cost 
per patient. 
    Public  health  costs.       Five of the 13 studies reported 
government costs of dengue prevention and control.  30,35,36,41,42  
Lok itemized the costs of vector control in Singapore, including 
person hours, equipment, and pesticides.  30  The Brazilian 
Ministry of Health  31   included costs of education, laboratory 
surveillance, and legislative activities.  35  Two Pan American 
Health Organization (PAHO) reports provided the annual 
cost of vector control for 23 countries in their region.  41,  42  
A study by Nathan evaluated the   Aedes aegypti   control 
program in 24 Caribbean and selected neighboring countries; 
all in the PAHO region.  36  
  Lok identified a common problem in allocation of costs for 
vector control programs; rarely were specific staff or equip-
ment solely designated for dengue.  30  As a result, if dengue 
were controlled through other means (e.g., vaccine), the associ-
ated reallocation of resources to other vector control activities 
would lead to savings in opportunity costs, but not necessarily 
in financial expenditures. This is particularly true when other 
diseases (e.g., yellow fever, Chikungunya) are transmitted by 
the same vector (e.g.,   Aedes   mosquitoes) necessitating contin-
ued   Aedes   control efforts. This is observed for yellow fever and 
Japanese encephalitis, both vaccine preventable diseases that 
include vector control programs as an integral part of their 
prevention and control plans.  74,  75   However, a true saving in 
vector control activities might occur if vaccination eliminated 
dengue epidemics with their attendant intensified activities 
and expenditures.  76,  77  
    Budget impact.    No reports were identified detailing country-
specific cost estimates for dengue vaccination programs as has 
been done for other vaccine preventable diseases.  78,  79   Such 
preplanning has been shown to facilitate introduction of a new 
vaccine.  80  
   Healthcare  system  perspective.    Four  studies  reported  dengue 
COI from the perspective of the healthcare system. Harling 
and others assessed the impact of travel associated disease 
cared for in the United Kingdom healthcare system, where 
dengue accounted for 2% of the total cost.  24  The study was 
limited because costs for hospitalized patients were estimated 
on a per-day basis without itemization. Wong and others used 
diagnostic billing codes (i.e., Australian National Diagnosis-
Related Group (AN DRG) version 3.1 [1996]) to estimate 
the direct medical costs for hospitalized dengue patients.  52  
Dengue was also the main focus of studies by Añez and others 
(Venezuela)  11   and Garg and others (India)  21   who used an 
average cost of hospitalization after summing accumulated 
costs associated with the study facilities. Añez and others 
multiplied this estimate by the reported number of cases,  11  
whereas Garg and others used a multiplication factor to 
account for under-reporting.  21  The latter study had several 
weaknesses including, the use of a multiplication factor and 
age distributions derived from Thailand instead of India.  21  
Because the age distribution and standards of care for dengue 
treatment often differ by region,  63,  81,  82   their estimates may 
not be valid. Furthermore, Garg and others used an average 
duration of illness based on all febrile illnesses rather than 
dengue, which have been shown to have a significantly longer 
duration of fever.  10  
   Household  perspective.     Dengue household impact studies 
have documented not only the financial burden of dengue 
but also intangibles such as emotional stress for an entire 
household.  25,27,28,47,50  Dengue is among the infectious diseases 
that can cause unexpected catastrophic medical costs for 
families living in low-income countries (a catastrophic cost 
has been defined as ≥ 40% of the capacity to pay, on the basis 
of a household’s non-subsistence effective income.  83   These 
costs are even greater when multiple cases occur in the same 
household, which is common during epidemics.  25,47,50  Parents 
often express fear for their children with regard to dengue, 
which likely affects health-seeking behavior and increases 
their willingness to spend and incur debt for perceived higher 484 BEATTY AND OTHERS
quality healthcare services.  50   The issue of debt is important 
because this has been shown to persist for more than a year 
in households where children have been hospitalized for 
dengue.  26,32,50,84  Loss of assets and ongoing debt are rarely 
accounted for in COI studies. Such variations have also been 
described for other diseases, such as malaria.  85,  86   Challenges 
with these studies include the uneven and seasonal changes in 
income that can alter impact  85,  86  and complexities of estimating 
the value of bartered goods and services. 
    Comparative  analyses.     Vaccines.     There were two published 
studies of potential cost-effectiveness of dengue vaccination 
compared with either vector control or case management 
( Table 3 ). 43,  44  In 1993 Shepard and Halstead estimated the cost-
effectiveness of immunization compared with vector control 
and case management in the context of two levels of healthcare 
system development—“developed” or “undeveloped” (e.g., 
Thailand and Laos, respectively).  43  Base-case assumptions 
included a 3.8% dengue incidence, 1.2 billion people at risk of 
infection, a two-dose vaccine regimen at US$17.50/dose with 
a US$0.50 administration cost per dose.  43   Costs of alternative 
control methods were US$0.46 per capita for chemical vector 
control and US$2.25 for environmental vector control. Direct 
medical costs for hospitalized DHF cases were estimated at 
US$200; non-hospitalized cases were not included. The authors 
found a dengue vaccine would be cost-effective (average 
US$1,440 per DALY saved and US$92,461/death averted) 
in countries with poorly developed healthcare delivery 
systems, but case management would be more cost-effective 
in countries classified as “developed.”  43   A sensitivity analysis 
indicated vaccine would become cost-effective in developed 
countries at ≤ US$7.00/dose. 
  A subsequent study (including the same authors) in 2004 
analyzed 10 Southeast Asian countries with an estimated pop-
ulation of 529 million and dengue incidence based on WHO 
reporting.  44   Other assumptions included a two-dose regimen 
costing US$0.50/dose in the public sector and $10/dose in the 
private sector, US$3.50/dose for vaccine administration, 1% 
annual disease incidence, treatment costs (direct and indi-
rect) of US$139 for DHF and US$4.29 for DF, and vector 
control costs of US$0.02–$3.56 per capita.  44   This  study  found 
vaccine to be potentially cost-effective (average US$50 per 
DALY, 52% because of reduction in premature mortality), at 
US$7.64/dose (weighted average for public and private sector 
including administration costs).  44   The difference in results of 
the two studies reflects wide differences of input assumptions, 
which makes it difficult to compare the results of the studies. 
The WHO has recently proposed guides that may help stan-
dardizing such analyses more.  87,  88  
   Vector  control.     There have been seven additional comparative 
studies that focused on vector control for dengue prevention 
( Table  3 ). 13,14,33,38,39,45,48  The study by Arthur D. Little, Incorporated 
reported that eradication of   Aedes aegypti   was more cost-
effective than on-going control in Latin America.  13  Although 
the studies by McConnell and others, Suaya and others, and 
Orellano and Pedroni also estimated the potential economic 
impact of control programs on disease incidence,  33,38,45  the studies 
by Osaka and others, Baly and others, and Tun-Lin and others 
prospectively compared outcome measures in intervention and 
control communities interventions.  14,39,48  Osaka and others used 
disease incidence as the outcome measure,  39  whereas Baly and 
others and Tun-Lin and others used larval indices.  14,48  Because 
of its randomized and multicenter, multicountry design, 
Tun-Lin and others was the most powerful study and effectively 
showed that targeted larval control was at least as effective 
as non-targeted control but at a lower cost except where the 
intervention incorporated social mobilization.  48  However, while 
the use of larval indices are correlated with the prevalence of 
human dengue infections,  89   outbreaks still occur at what are 
considered low larval indices.  90   
    Stated  preferences  research.     In the one identified WTP 
study, Palanca-Tan asked 205 persons living in metropolitan 
Manila to consider a single dose, safe and efficacious dengue 
vaccine.  40  Their willingness to pay for such a vaccine was 
elicited by a dichotomous choice approach,  91   with an average 
that ranged from US$27 to $32.  40   The WTP studies also 
captured psychological and social aspects of health outcomes 
that cannot be assessed through traditional cost-of-illness 
studies (e.g., satisfaction the individual derives from using the 
resources or the value attached to future use).  88   Perhaps, more 
important than preferred cost, this type of study can estimate 
public demand for a vaccine.  19  
  Dengue can become such an important political issue that 
government officials may lose favor as a result of choices made 
during dengue epidemics.  92–  95   Indeed, policymakers in four 
Southeast Asian countries (Cambodia, Indonesia, Philippines, 
and Vietnam) expressed a high level of concern regarding DF 
and a great need for a vaccine.  19   In addition, they indicated 
that disease surveillance studies, in-country vaccine trials or 
pilot projects, and studies on the economic burden of dengue 
and the cost-effectiveness of dengue vaccines were necessary 
for informed decision making regarding vaccine introduction.  19  
Surveys of policymakers may be informative in predicting 
public support for vaccine introduction and their importance 
for decision making should not be underestimated.  19  For exam-
ple, public concern about disease awareness rather than con-
siderations of cost-effectiveness drove recommendations for 
use of meningococcal vaccine in college students in the United 
States and other countries.  96,  97  
    DISCUSSION 
  On the basis of the review of available studies, the expert 
panel recommended types of economic studies they thought 
would fill information gaps related to development and intro-
duction of dengue vaccines ( Table 4 ). In addition, they assigned 
priorities and suggested a time frame during which these stud-
ies should be completed; primarily influenced by estimated 
time for first approval of a dengue vaccine. Finally, the panel 
indicated their perception of importance of these studies to 
decision-makers involved in development or introduction of a 
dengue vaccine. Below are specific comments for the recom-
mended studies (  Table 4  ). 
       Disease  burden.     Accurate disease incidence data are 
required to provide robust estimates of disease burden 
across the regions where dengue is endemic. National dengue 
surveillance programs are designed to detect disease trends 
and detect outbreaks and their sensitivity and specificity is 
often affected by program budgets. For this reason, further 
studies are required to quantify under detection and under-
reporting. Dengue incidence studies should be prospective, 
performed in defined populations that are representative of 
the community, and include a wide range of ages. Febrile illness 
should be the starting point to ascertain dengue cases, which 
should be defined by well-established and validated laboratory 485 HEALTH ECONOMICS OF DENGUE
methods that include molecular diagnostics for DENV and/or 
DENV NS1 antigen detection and immunoglobulin M (IgM) 
anti-DENV.  98  
  The results from these studies can then be compared with 
national surveillance data gathered in the same region to pro-
vide reasonable multiplication factors to account for under-
reporting. Alternatively, a more rigorous method for estimating 
the degree of disease under-reporting is to perform a capture–
recapture study.  62  
  Additional prospective COI studies are needed that include 
representative sampling from each type of heath care facility 
in both the public and private sectors, preferably over multiple 
years. Because DHF and DF are not classified in a uniform 
way across all dengue endemic regions,  99   the expert panel rec-
ommended that cases be categorized by outcomes, such as 
non-hospitalized, hospitalized, or death. Adjustment is needed 
for age-specific differences in rates of symptomatic disease in 
children and adults. Many studies have used age categories of 
0–15 years and > 15 years, which was considered the minimum 
acceptable age stratification by the expert panel. 
 The panel stressed that future studies should clearly indicate 
assumptions, include costs, and use dengue- and country-spe-
cific data. Itemized lists of costs appropriate for micro-costing 
of programs have been published,  100   and WHO has devel-
oped guides for economic studies.  87,  88   Comprehensive mul-
tiperspective studies that document the total cost of illness 
but also allow for analysis from each perspective are useful 
to decision makers. The exceptions are budget impact studies 
of vaccination programs conducted from the government per-
spective, which are used to determine best approaches to vac-
cine implementation. 
   Comparative  analyses.     Additional comparative analyses to 
estimate the potential economic impact of a dengue vaccine are 
a high priority. The experts recommended cost-effectiveness or 
cost-utility analyses to avoid the inherent difficulties of cost-
benefit analyses associated with converting benefits, including 
lives saved, into monetary units. These studies should include: 
1) clearly defined and referenced assumptions; 2) country-
specific or internationally vetted costs of vaccination and 
potential vaccine related adverse events, and added costs 
of post-implementation surveillance to monitor safety and 
efficacy of a new vaccine; 3) estimated impact on mortality, 
as policymakers may expect this to be high, despite the fact 
that dengue is a relatively low mortality disease; 4) reporting 
of cost-effectiveness in natural units such as hospitalizations 
averted, deaths averted, life-years gained, and as DALYs 
averted or QALYs gained; and 5) a discount rate of 3% for 
both costs and effects as recommended in WHO guides.  88  
The meeting participants agreed that recently developed 
WHO Guides for standardization of economic evaluations 
of immunization programs and economic consequences of 
disease should be followed to allow comparability between 
studies.  87,  88   Furthermore, a number of specific issues related to 
model-based economic evaluation of vaccines as opposed to 
curative drugs, are relevant but outlined elsewhere.  53,  101  
  Designing cost-effectiveness studies before a vaccine has 
been fully evaluated requires assumptions about variables 
such as efficacy and effectiveness, dosage and costs. The panel 
advised the following: 1) assume first generation tetravalent 
dengue vaccines would require at least a two-dose regimen, 
and likely three doses; 2) determine the threshold price for a 
vaccine to be cost-effective rather than assigning a specific cost, 
because it is difficult to predict cost (public and private) for a 
vaccine that has not been marketed; and 3) conduct sensitivity 
analyses on epidemiological, effectiveness, and cost estimates to 
determine the uncertainty of the cost-effectiveness estimates. 
  A static cost-effectiveness model developed for pandemic 
influenza,  102   has been shown to stimulate interest and further 
country-specific economic research (Meltzer MI, personal 
communication) and could have the same effect for dengue. 
Dynamic transmission models are also needed and should 
account for serotype-specific immunity, herd protection, vec-
tor-host interactions, seasonal variations in disease transmis-
sion, and age-specific differences in disease incidence and 
severity. These models in turn should be coupled with eco-
nomic models to assist in choosing the most efficient and cost-
effective options for intervention. 
   Stated  preferences  research.     The panel recommended that 
future studies of this type include an assessment of acceptance 
of a potential vaccine with varying levels of effectiveness and 
price, and questions that allow comparisons with prevention 
of other diseases. 
   Limitations.     By its very nature, the systematic literature 
review in this work captured mainly published studies, and is 
 Table 4 
    Dengue health economic expert panel opinion of the priority,  *   timing,  †   and perceived importance  ‡   of additional dengue health economic studies 
to audiences with interest in a dengue vaccine   
 
Disease burden
Budget impact of vaccine 
implementation Comparative analyses Stated preference research Without monetization With monetization (cost of illness)
Need-based priority 1 2 2 1 3
Audience
 Donors  §  S+ M0 M+ M+ S+
 Vaccine  manufacturers S+ M+ M+ M+ S+
  Public health community  ¶  S+ M0 M– M+ M0
  Private healthcare insurers L0 S+ M+ M+ M+
Governments & advisory 
bodies
M+ S0 M+ M+ M+
 Clinician  organizations L0 M– L– M0 M–
 Healthcare  providers L0 M– L– M0 M–
 Consumers|| L0 M– L– M0 L–
    *     Need-based priority was rated numerically, 1 = urgent, 2 = needed, 3 = optional.   
    †     Timing or event horizon for commencing new studies over the next 5 years; the results to be most useful: S = Short term (1–2 years), M = Midterm (2–4 years), L = Long term (5–6 years).   
    ‡     Perceived importance to various audiences with interest in a dengue vaccine was rated as follows: (+) = Higher interest, 0 = Medium interest, (–) Lower interest.   
    §     Donors are those groups providing funding, e.g., development banks.   
    ¶     The public health community includes non-governmental organizations, the World Health Organizations, national and local ministries of health, etc.   
    ||     Consumers of a dengue vaccine include the general public including special groups (e.g., military, travelers).   486 BEATTY AND OTHERS
therefore subject to publication bias. We aimed to minimize 
potential exclusions of valuable sources by searching the 
reference lists of retained studies ( Figure 1 ) to identify relevant 
books, unpublished data, evaluations, and dissertations. 
Furthermore, we did not restrict the review by language. That 
said, only English, Spanish, French, and Portuguese were 
encountered during the search. 
    CONCLUSION 
  Although dengue is an important vector-borne disease, the 
economic literature is relatively sparse and results have often 
been conflicting because of use of inconsistent assumptions. 
This review of the literature captures the available informa-
tion at a point in time. We presume that as new information 
becomes available it will be added to this information base. 
Health economic research specific to dengue is urgently needed 
to ensure informed decision making on the various options for 
controlling and preventing this disease—an option, which in 
the not too distant future, is likely to include vaccination. 
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